Magazine Article | October 1, 2021

Gearing Up For A Biotech M&A Boom

Source: Life Science Leader

By Todd Berry

At the height of the pandemic, economists and sociologists alike prophesied a second Roaring Twenties, during which people would emerge from their quarantine bubbles ready to throw money at restaurants, theaters, and anything else that promised socialization and distraction from memories of COVID-19. While society at large may not yet live up to the fantasies conjured in quarantine, the business of biotech mergers and acquisitions really does seem ripe for a resurgence.

Biotech M&A was slow in the first half of 2021, but that may be changing, with emerging trends indicating that a biotech M&A boom could be on the horizon. If your biotech is hoping to be acquired by a larger pharma company, it’s crucial that you start preparing now.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader